Regeneron Pharmaceuticals | REGN - Cash And Equivalent


Regeneron Pharmaceuticals reported $3.66B in Cash and Equivalent for its fiscal quarter ending in September of 2026.





Cash And Equivalent Change Date
AbbVie USD 10.77B 4.2B Sep/2026
Agenus USD 18.74M 16.26M Jun/2026
Agios Pharmaceuticals USD 128.55M 28.9M Sep/2026
Alnylam Pharmaceuticals USD 1.75B 46.02M Sep/2026
Amgen USD 13.19B 799M Sep/2026
Astellas Pharma JPY 244.7B 36.91B Jun/2026
AstraZeneca USD 4.89B 2.67B Jun/2026
Biogen USD 1.3B 18.9M Sep/2026
BioMarin Pharmaceutical USD 736.01M 138M Sep/2026
Bristol-Myers Squibb USD 9.57B 852M Sep/2026
Eli Lilly USD 4.89B 4.07B Sep/2026
Gilead Sciences USD 3.18B 4.45B Jun/2026
GlaxoSmithKline GBP 3.1B 337M Jun/2026
Incyte USD 3.85B 127.8M Sep/2026
Ionis Pharmaceuticals USD 350.06M 1.57B Jun/2026
J&J USD 16.91B 3.51B Sep/2026
Kyowa Hakko Kirin JPY 218.77B 15.83B Dec/2025
Merck USD 9.55B 2.7B Sep/2026
Moderna USD 1.2B 528M Sep/2026
Neurocrine Biosciences USD 641.5M 309.1M Sep/2026
Novartis USD 8.87B 1.25B Sep/2026
Novartis USD 8.87B 1.99B Sep/2026
Pfizer USD 1.82B 848M Sep/2026
Puma Biotechnology USD 53.52M 1.14M Sep/2025
Regeneron Pharmaceuticals USD 3.66B 1.2B Sep/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 6.35B 806M Jun/2026
Sarepta Therapeutics USD 472.76M 98.39M Sep/2026
Teva Pharmaceutical Industries USD 4.08B 430M Sep/2026
Ultragenyx Pharmaceutical USD 150M 25M Sep/2026
United Therapeutics USD 1.19B 614.3M Sep/2026
Vertex Pharmaceuticals USD 6.3B 1.55B Sep/2026